Results 131 to 140 of about 24,787 (310)

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Journal of Dermatological Treatment
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic
C. Grote, F. Zirkenbach, J. N. Wagner, M. Augustin   +3 more
doaj   +1 more source

Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System [PDF]

, 2021
Sainan Bian, Pingping Zhang, Lisha Li, Zixi Wang, Le Cui, Yingyang Xu, Kai Guan, Bin Zhao, Zhuang‐Gui Chen   +8 more
openalex   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Suspensión de dupilumab en dermatitis atópica. ¿es una opción la suspensión? Seguimiento de 12 casos

Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Antecedentes: Dupilumab es el primer tratamiento biológico aprobado para la dermatitis atópica (DA) moderada a severa con excelente perfil de seguridad y eficacia pero hasta el momento con poca literatura sobre la duración de tratamiento.   Objetivo:
Mirian Casas-Vargas, Cindy Cáceres-Salamanca, María Fernanda Ordóñez-Rubiano   +2 more
doaj   +1 more source

Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines

, 2021
Michael E. Wechsler, Adelmir Souza‐Machado, Christine Xu, Xuezhou Mao, Upender Kapoor, Faisal A. Khokhar, John T. O’Malley, Christopher D. Petro, Veronica Mas Casullo, Leda Mannent, Paul J. Rowe, Juby A. Jacob‐Nara, Marcella Ruddy, Elizabeth Laws, Lisa A. Purcell, Megan Hardin   +15 more
openalex   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Allergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery, Rüçhan Ekren, Emilie Bérard, Aurélie Du‐Thanh, Hugo Rimet, Fatma Jendoubi, Vanina Lenief, Nadia Raison‐Peyron, Amel Bouznad, Maria P. Konstantinou, Jonathan Rioual, Lilian Basso, Juliette Mouiren, Manon Boussier, Brigitte Milpied, Cristina Bulai Livideanu, Louise Jaulent, Florence Hacard, Marine A. Lefevre, Audrey Nosbaum, Julien Seneschal, Marc Vocanson, Carle Paul, Nicolas Gaudenzio, Marie Tauber, on behalf of the French Atopic Dermatitis Network from de GREAT Research group   +25 more
wiley   +1 more source

Omalizumab en práctica clínica dermatológica. Indicaciones, mecanismo de acción y factores predictivos de respuesta [PDF]

, 2019
El Omalizumab es un anticuerpo monoclonal anti-IgE aprobado para el tratamiento del asma y de la urticaria crónica idiopática refractaria al tratamiento con antihistamínicos H1.
Fernández Gutiérrez, Eva, García-Peñuela Arrechea, Íñigo   +1 more
core  

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study

, 2023
Dawei Huang, Yuexin Zhang, Yingyuan Yu, Yuxiong Jiang, Luyang Kong, Yangfeng Ding, Yuling Shi, Yunlu Gao   +7 more
openalex   +1 more source

Dupilumab‐Associated Palmar Erythema Successfully Treated With Fluconazole

Australasian Journal of Dermatology, EarlyView.
Katina J. Selvaraj, Geoffrey Lee
wiley   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source